Amyl Therapeutics

Amyl Therapeutics is a preclinical-stage biotechnology company founded in 2020 and based in Belgium. The company's mission revolves around pioneering a breakthrough approach to treating severe peripheral amyloid protein misfolding diseases. With the slogan "Restoring clarity in amyloid diseases," Amyl Therapeutics aims to develop novel therapies that recognize and target multiple misfolded proteins, ultimately making a transformative impact on the lives of patients affected by neurodegenerative diseases such as Alzheimer's and Parkinson's diseases, or by systemic amyloidosis.

The company's strategy is underpinned by an experienced team with deep drug development expertise, and productive collaborations with world-class advisors and partners. Amyl Therapeutics recently secured a significant €5.30M Series A investment on 07 November 2023, with backing from notable investors including Mérieux Equity Partners, Noshaq, and Evren Ucok.

Overall, Amyl Therapeutics is positioned as a promising player in the biotechnology, health care, and life sciences industries, offering potential opportunities for venture capital firms seeking exposure to innovative solutions in the treatment of amyloid diseases.